Tu 2012.

Methods	RCT
Participants	67 participants with acute ischaemic stroke (age and sex unknown) Time of randomisation after stroke onset: unknown Treatment: 34 participants at randomisation and all completed the trial Control: 33 participants at randomisation and all completed the trial
Interventions	Treatment: phosphopyridoxal buflomedil (20 mg, twice per day, ivgtt, 14 days) + control intervention Control: edaravone (ivgtt) + gangliosides (ivgtt) + aspirin (po) 14 days
Outcomes	Time of outcome assessment: by the end of 14‐day treatment SSS Haemorheological indices (platelet aggregation rate, whole blood viscosity, plasma viscosity, red blood cell deformation, fibrinogen) Adverse events (including renal and hepatic function tests)
Notes	Combination of buflomedil with edaravone and gangliosides and aspirin Funding: not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"Randomised" but did not report the methods of randomisation
Allocation concealment (selection bias)	Unclear risk	Insufficient information was reported to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	High risk	Interventions used in the 2 groups were visibly different
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	The trial did not address this outcome
Incomplete outcome data (attrition bias) All outcomes	Low risk	No missing outcome data
Selective reporting (reporting bias)	Unclear risk	The protocol was not available. Insufficient information to permit judgement